THE USE OF DEXTRAN IN GYNECOLOGICAL POWDERS CONTAINING LACTIC ACID COMPLEXED WITH CHITOSAN

• Authors: Katarzyna Małolepsza-Jarmołowska
• Languages of publication: EN

Abstracts

EN

Powders for gynecological use pass under natural conditions in gels covering the vaginal mucosa. This study has shown the impact of used excipients and the ratio of lactic acid to chitosan on pH, dynamic viscosity and adhesiveness of methylcellulose gels obtained from powders. All gels with complexes in the ratios of 1:1 and 2:1 (lactic acid:chitosan) showed a pH in the physiological range 3.5-5.0 at 37°C. The addition of dextran and excipients to these complexes allows various formulations over a wide range of pH to be obtained. Rheological investigations revealed an increase in the dynamic viscosity of preparations containing lactic acid complexed with chitosan and dextran in comparison to gels without dextran. Studies of the work of adhesion showed the effect of glycerol, 1,2-propylene glycol and their concentrations on the value of the work of adhesion. The presented work shows that it is possible to obtain gels with high adhesion properties to vaginal mucous membrane.

Keywords

EN

anti-inflammatory drugs; hydrophilic powders; lactic acid complexed with chitosan; physiological environment of vagina; vaginal infections; vaginal mucosa

• Publisher: Sieć Badawcza Łukasiewicz - Polskie Towarzystwo Chitynowe
• Journal: Progress on Chemistry and Application of Chitin and its Derivatives
• Year: 2017
• Volume: 22
• Pages: 143-150

Contributors

author

Katarzyna Małolepsza-Jarmołowska

• Chair and Department of Pharmaceutical Technology, Faculty of Pharmacy The “Silesian Piasts” memorial Medical University of Wroclaw, 50-556 Wrocław, Borowska 211A Street, Poland.

References

• [1] Schwebke JR; (2009) New Concepts in the Etiology of Bacterial Vaginosis. Curr. Infect. Dis. Rep. 11, 143 – 147. DOI: 10.1007/s11908-009-0021-7
• [2] Brandt M, Abels C, May T, Lohmann K, Schmidts – Winkler I, Hoyme UB; (2008) Intravaginally applied metronidazole is as effective as orally applied in the treatment of bacterial vaginosis, but exhibits significantly less side effects. Eur. J. Obstet. Gynecol. Reprod. Biol. 141, 158 – 162. doi.org/10.1016/j.ejogrb.2008.07.022
• [3] Donders GGG, Larson PG, Platz – Christensen JJ, Hallen A, Meijden W, Wölner – Hanssen P; (2009) Variability in diagnosis of clue cells, lactobacillary grading and white blood cells in vaginal wet smears with conventional bright light and phase contrast microscopy. Eur. J. Obstet. Gynecol. Reprod. Biol. 145, 109 – 112. doi.org/10.1016/j.ejogrb.2009.04.012
• [4] Kubis AA, Małolepsza-Jarmołowska K; (1996) Studies on gynecological hydrophiling preparations comprising lactic acid. Part 1: Effects of lactic acid and hydrophiling agents on physical and chemical properties of methylcellulose gels. Pharmazie 51, 989 – 990.
• [5] Małolepsza-Jarmołowska K, Kubis AA; (1999) Studies on gynecological hydrophilic lactic acid preparations. Part 2: Effects of Eudragit® E-100 on properties of methylcellulose gels. Pharmazie 54, 441 – 443.
• [6] Małolepsza-Jarmołowska K, Kubis AA; (2000) Studies on gynaecological hydrophilic lactic acid preparations. Part 3: Effects of chitosan on the properties of methylcellulose gels. Pharmazie 55, 610 – 611.
• [7] Małolepsza-Jarmołowska K, Kubis AA; (2001) Studies on gynaecological hydrophilic lactic acid preparations. Part 4: Effects of polyvinyl pyrrolidone K-90 on properties of methylcellulose gels. Pharmazie 56, 160 – 162.
• [8] Małolepsza-Jarmołowska K, Kubis AA, Hirnle L; (2003) Studies on gynaecological hydrophilic lactic acid preparations. Part 5: The use of Eudragit® E-100 as lactic acid carrier in intravaginal tablets. Pharmazie 58, 260 – 262.
• [9] Małolepsza-Jarmołowska K, Kubis AA, Hirnle L; (2003) Studies on gynaecological hydrophilic lactic acid preparations. Part 6: Use of Eudragit® E-100 as lactic acid carrier in intravaginal tablets. Pharmazie 58, 334-336.
• [10] Małolepsza-Jarmołowska K; (2006) Studies on gynaecological hydrophilic lactic acid preparations. Part 7: Use of chitosan as lactic acid carrier in intravaginal tablets (globuli vaginales). Pharmazie 61, 780 - 782.
• [11] Małolepsza-Jarmołowska K; (2007) Studies on gynaecological hydrophilic lactic acid preparations. Part 8: Use of chitosan as lactic acid carrier in intravaginal tablets. Acta Pol. Pharm. 64, 69 - 72.
• [12] Małolepsza-Jarmołowska K; (2010) The effect of poloxamer 407 on the properties of hydrophilic gels containing lactic acid complexed with chitosan. Monograph vol. XV ed. by M. Jaworska „Progress on Chemistry and Application of Chitin and Its Derivatives“ 15, 143-148.
• [13] Małolepsza-Jarmołowska K; (2014) Research of pharmaceutical properties of hydrophilic powders containing lactic acid complexed with chitosan „Progress on Chemistry and Application of Chitin and Its Derivatives“ XIX, 79-86. DOI:10.15259/PCACD.19.09

• Document Type: article